Statistics in Biopharmaceutical Research

Papers
(The H4-Index of Statistics in Biopharmaceutical Research is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 Pandemic63
The Role of p-Values in Judging the Strength of Evidence and Realistic Replication Expectations40
Machine learning for clinical trials in the era of COVID-1938
Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-1936
The Current Landscape in Biostatistics of Real-World Data and Evidence: Causal Inference Frameworks for Study Design and Analysis31
Robust Design and Analysis of Clinical Trials With Nonproportional Hazards: A Straw Man Guidance From a Cross-Pharma Working Group31
Clinical Trials Impacted by the COVID-19 Pandemic: Adaptive Designs to the Rescue?27
Biostatistical Considerations When Using RWD and RWE in Clinical Studies for Regulatory Purposes: A Landscape Assessment24
Challenges in Assessing the Impact of the COVID-19 Pandemic on the Integrity and Interpretability of Clinical Trials22
Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials—Application of the Estimand Framework22
The Hazards of Period Specific and Weighted Hazard Ratios19
The Current Landscape in Biostatistics of Real-World Data and Evidence: Clinical Study Design and Analysis18
Use of Nonconcurrent Common Control in Master Protocols in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion14
0.044420003890991